Do you alter treatment in high grade serous ovarian cancer patients receiving neoadjuvant chemotherapy with stable disease after 3 cycles?  

This is always a challenging clinical situation, as the intent of neoadjuvant chemotherapy is to reduce disease burden sufficiently to enable cytoreduction to microscopic residual disease. If disease remains stable despite administration of neoadjuvant therapy, it often denotes a biologically aggres...